Health care transfer gears to incorporate weight loss medications, cash anti-obesity prosperity
The company is increasing its products to include GLP-1 drugs such as Ozempic and Mounjaro – for the treatment of type 2 diabetes, and in some cases obesity – and expects its GLP-1 partner program to exceed the revenue of Healthify’s major revenues within three to four years of sanitation. Mint In the interview.
The HealthTech company, which started as a calorie and nutrition tracking app, expects a surge in demand for weight loss medication in India.
“As prices fall, adoption of drugs will happen very quickly. What we want to do is a pioneer companion solution,” Vashisht said, acknowledging that immediate adoption may be slow. “End of the day, I saw a world where every hospital has a medical weight loss program, but one common thing is that everyone needs lifestyle support.”
The company has launched a product that combines GLP-1 drug (glucagon peptide-1 receptor agonist) with lifestyle coaches and lifestyle coaches for people who have taken the medication. It is tied to the online pharmacy Tata 1mg, which will provide medication and diagnostic services.
Healthify’s three-month plan includes 12 doses of Mounjaro along with nutritionists, trainers and nutritionists, as well as GI kits, as well as costs ₹65,000. This includes tracking key metrics on sanitary applications. Six months plan fee ₹80,000, one year ₹According to the platform’s website, there are 100,000.
The startup recorded its first earnings quarter in India in January and hopes to maintain that momentum this year.
“The idea is to continue to be profitable. We will be profitable for India’s first fiscal year,” Vashisht said. “GLP-1 is one of the leverages to get that.”
Healthify hopes to address two key issues with weight loss medications: side effects that affect their gastrointestinal system when taking GLP-1 medications, and the trend for most Ozempic or Mounjaro users, once the medication is stopped, you need to lose weight to maintain weight loss.
US Market
Last year, Healthify entered the U.S. market and plans to expand its business there this year.
“We have a good contact with what’s going on in the U.S. … What we’ve seen is that 20% of North American adults have tried it [GLP-1s] already. This has taken a major management approach and a very significant change. ”
Indeed, conversations about weight loss have changed a lot in countries like the United States, and these drugs have been around for several years.
Traditional weight loss athletes, such as gyms, calorie tracking apps and health supplements, need to revamp and adapt to changing conversations or risks becoming obsolete, Mint Earlier reported.
Weightlifters of the U.S. health giant are reportedly filing for bankruptcy, and he announced a partnership with Eli Lilly on Tuesday to make it easier to get Lilly’s weight loss pill Zepbough.
“At the platform level, applications may need to integrate GLP-1 drug tracking. The new KPI (primary performance indicators) will now end,” Kiran Mahasuar, assistant professor of strategy, innovation and entrepreneurs at IMT Ghaziabad, told IMT Mint. “You will have to look at lean quality retention, satiety scores… Now, the main focus is on the calorie deficit, which will shift to nutrient density tracking.”
In India, India, the world’s third largest obese population, has also experienced awareness and demand for weight loss solutions. Eli Lilly launched the weight loss drug Mounjaro in India in March, priced at ₹17,500 doses per month 5 mg. The company said Novo Nordisk will start selling its weight loss drugs in India this year at competitive pricing.
Indian general drug manufacturers Cipla Ltd, Dr. Reddy’s Laboratory Ltd, Lupine Ltd, Natco Pharma Ltd, Mankind Pharma Ltd and Biocon Ltd are preparing a copy of Semaglutide – an anti-diabetic and anti-abdominal drug. Sun Pharmaceutical Industries Ltd, India’s largest drugmaker, is using its own GLP-1 drug.
Globally, the GLP-1 market is expected to grow to US$100 billion by 2030. In India, patients started using drugs like Mounjaro even before the country was launched and sourced them from overseas through the gray market. The market reportedly doubled in size, with the size of people with diabetes in 2024 to $3.6 billion. British Journal of Medicine.
Weight loss awareness
Current drug pricing and alliance plans make them inaccessible to most of India’s population. However, drug prices are expected to fall, which will also reduce prices on platforms like Healthify.
The startup has enhanced its AI playback over the past few quarters and will begin integrating more AI capabilities into GLP-1 tracking and companion products.
The buzz around these drugs also raises greater awareness of weight loss for those who are not eligible for prescription medications or cannot afford it.
“There is a clear trend there to turn to better engagement and use,” Vashisht said. “Even non-GLP-1 use of tools like nutrition tracking will increase significantly.”
The platform plans to launch its GLP-1 companion program in the U.S. in the coming months and expand it there. Healthify is building a B2B2C-set partnership with India’s top hospital chain. Now other startups such as Elevate also offer doctor-led weight management services that combine GLP-1 with nutrition and coaching.
“The competition here will also be held in the next few months,” Vashisht said.
But hygiene is relying on its talent products, including coaches from the United States, a platform dominated by doctors and brand value to maintain its position.
